Navigation Links
Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy

MELBOURNE, Australia, Nov. 14 /PRNewswire/ -- Swiss experts have abandoned the over 100 year old tuberculin skin test (TST) favouring the use of interferon-a release assays such as QuantiFERON(R)-TB Gold (QFT(TM)) for screening patients for tuberculosis (TB) infection prior to initiating biological treatments (such as anti-TNF-a therapy). In recommendations published in the current issue of the Swiss Medical Weekly, experts advocate the use of QFT(TM) in place of the TST, as it is more accurate (sensitive & specific) than the TST in individuals with immune suppression and provides rapid and reproducible results. These recommendations come after the recent approval of the In-Tube format of QFT(TM) by the U.S. Food and Drug Administration(FDA) and its widespread use in Europe and Asia for a number of years.

Biological treatments (like anti-TNF-a) are increasingly being used to treat rheumatoid arthritis, dermatological conditions like psoriasis and gastroenterological conditions like Crohn's disease and ulcerative colitis. Patients receiving anti-TNF-a therapy are at a higher risk of developing tuberculosis during treatment than patients with similar diseases not receiving anti-TNF-a therapy or the general population. Most cases of TB appear due to reactivation of latent TB infection and not new (or de novo) infection, and the Swiss recommendations advocate screening all patients for TB infection prior to initiating anti-TNF-a therapy. In addition to QFT(TM) use, screening should be based on a detailed medical history and a chest x-ray.

Preventive treatment should be offered to all patients with evidence of latent tuberculosis infection before starting anti-TNF-a therapy. For patients with a positive QFT(TM) result, the experts unanimously supported appropriate preventive drug treatment for TB.

The group of experts (in rheumatology, gastroenterology & pneumology) published the recommendations in the current issue of Swiss Medical Weekly, the official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine and the Swiss Respiratory Society.


Swiss Med Wkly 2007; 137:621-622.

About QuantiFERON(R)-TB Gold (QFT(TM)):

QFT(TM)- - a simple blood test -- is the first major advancement in TB diagnosis since the introduction of the tuberculin skin test (TST) over 100 years ago. The QFT(TM) test is based on measurement of a cell mediated immune response in TB-infected individuals. The T cells of these individuals are sensitized to TB, and respond to stimulation with peptides simulating those expressed by the TB causing bacteria, secreting a cytokine called interferon- a. QFT(TM) accurately measures the interferon-a response in a sensitive enzyme assay. QFT(TM) is unaffected by previous BCG vaccination and most other mycobacteria.

Unlike the TST, it requires only one patient visit, is a controlled laboratory test, and provides an objective, reproducible result that is not subject to interpretation based on a patient's relative risk factors for TB exposure.

About Cellestis:

Cellestis is a listed Australian biotechnology company commercializing QuantiFERON(R) technology for diagnosing TB and other diseases worldwide. The Company operates through subsidiaries in the USA, Europe and Australia.

For more information, visit or please contact one of our local spokespersons at:

Cellestis International


Tel: +61 3 9571 3500 (tel)

(Contact Mr. George Dragovic)

Cellestis Europe


Tel: +49 6151 428 590

(Contact Mr. Paul Lebeau)

Cellestis Inc.


US Toll free: 800 519 4627

(Contact Mr. Mark Boyle)

SOURCE Cellestis International
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Celebrity Designer Ty Pennington to Host ADHD Experts on Call Program
3. California IVF Experts Tap Ethics Committee for Guidance
4. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
5. International Diabetes Experts Call for Stepped-Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact
6. Report recommends off-site disposal of secondary waste
7. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
9. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
10. Report recommends off-site disposal of secondary waste
11. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
Post Your Comments:
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
Breaking Biology News(10 mins):